Kickstart your portfolio with a U.S. stock on us
Sign up and fund a new Wall St account and get a full U.S. share.Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.T&Cs apply
Innoviva, Inc.
About INVA
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
Find out what a historical investment in Innoviva, Inc. would be worth today using our INVA stock calculator.
Market Capitalisation
$1.62B
Price-earnings ratio
-
Dividend yield
0.00%
Volume
1M
High today
$22.85
Low today
$21.78
Open price
$22.83
52-week high
$25.15
52-week low
$16.52
Ready to start your investing journey with Stake?
Open an accountHow do I buy INVA shares in Australia?
Buying INVA shares in Australia can be done through an online investing platform, such as Stake. Follow the simple steps below to start investing in Innoviva, Inc. in minutes.
- Sign up with some I.D. and zero paperwork
- Add funds to your account
- Make your first investment in INVA
What is the ticker symbol of Innoviva, Inc.?
The ticker symbol for Innoviva, Inc. is INVA.
How much is one share of INVA?
One share of INVA is valued at $22.01 as of 17 May 2026.
What is the market capitalisation of Innoviva, Inc. INVA?
As of 17 May 2026 Innoviva, Inc. has a market cap of $1.62B.
What is the P/E ratio of INVA?
The Price to Earnings ratio of INVA is 3.79.
What is the Earnings Per Share of INVA?
The Earnings Per Share of INVA is $6.04.
What is the 52-week high for Innoviva, Inc. stock?
The Innoviva, Inc. 52-week high stock price is $25.15.
What is the 52-week low for Innoviva, Inc. stock?
The Innoviva, Inc. 52-week low stock price is $16.52.
Can I buy INVA shares through Stake, an investing platform like CommSec, Selfwealth or Superhero?
Yes, the Stake investing platform allows you to buy INVA shares and over 12,000 more stocks and ETFs across the ASX and Wall St.
This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.
Invest in INVA on Stake
- Buy INVA from US$3 brokerage
- Invest in 9,500+ U.S. stocks and ETFs
- Own a slice of INVA from only US$10 with fractional shares
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
INVA related stocks